936-16-3

Usage

Uses

Used in Pharmaceutical Industry:
2,3-DIHYDRO-1,1-DIOXO-1,2-BENZISOTHIAZOLE is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique chemical structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 2,3-DIHYDRO-1,1-DIOXO-1,2-BENZISOTHIAZOLE serves as an intermediate in the production of agrochemicals, such as pesticides and herbicides. Its incorporation into these products enhances their effectiveness in controlling pests and weeds.
Used in Dye Industry:
2,3-DIHYDRO-1,1-DIOXO-1,2-BENZISOTHIAZOLE is utilized as an intermediate in the synthesis of dyes, contributing to the development of new colorants with improved properties and applications in various industries, such as textiles and plastics.
Used as a Polymer Stabilizer:
2,3-DIHYDRO-1,1-DIOXO-1,2-BENZISOTHIAZOLE is used as a stabilizer in polymers to enhance their durability and resistance to degradation. Its incorporation into polymers helps maintain their structural integrity and extends their lifespan.
Used as a Corrosion Inhibitor in Metalworking Fluids:
In the metalworking industry, 2,3-DIHYDRO-1,1-DIOXO-1,2-BENZISOTHIAZOLE is employed as a corrosion inhibitor in metalworking fluids. Its addition to these fluids helps prevent the corrosion of metal surfaces during manufacturing processes, ensuring the longevity and quality of the final product.
Used in Antimicrobial and Anti-Fungal Applications:
Due to its antimicrobial and antifungal properties, 2,3-DIHYDRO-1,1-DIOXO-1,2-BENZISOTHIAZOLE is used in various industrial and agricultural applications to control the growth of harmful microorganisms. Its incorporation into products and processes helps maintain cleanliness and prevent contamination.
It is crucial to handle 2,3-DIHYDRO-1,1-DIOXO-1,2-BENZISOTHIAZOLE with care, as it may pose health risks if not properly managed. Proper safety measures should be taken during its production, use, and disposal to minimize potential hazards.

InChI:InChI=1/C7H7NO2S/c9-11(10)7-4-2-1-3-6(7)5-8-11/h1-4,8H,5H2

Upstream product

• 81-07-2 saccharin 
• 27148-03-4 thiosaccharine 
• 567-19-1 3-chloro-1,2-benzisothiazole 1,1-dioxide 
• 88-19-7 methyl 2-(aminosulfonyl)benzoate 
• 59777-72-9 ethyl 2-(aminosulfonyl)benzoate 
• 65270-84-0 2-(hydroxymethyl)benzenesulfonamide 
• 1373318-58-1 2-(ethoxymethyl)benzenesulfonamide 
• 7664-93-9 sulfuric acid 

Downstream Products

• 1245607-48-0 2-(3-fluoro-5-hydroxyphenyl)-2,3-dihydrobenzo[d]isothiazole-1,1-dioxide 

Relevant academic research and scientific papers

Synthesis and diabetic neuropathic pain-alleviating effects of 2N-(pyrazol-3-yl)methylbenzo[d]isothiazole-1,1-dioxide derivatives

A novel series of fused-benzensulfonamide 2-N-(pyrazol-3-yl)methylbenzo[. d]isothiazole-1,1-dioxide derivatives was designed and synthesized as metabolically stable T-type calcium channel inhibitors. Several compounds, 9, 10, and 17, displayed potent T-type channel inhibitory activity. Among them, compounds 10 and 17 showed good metabolic stability in human liver microsomes, and low hERG channel and CYP450 inhibition. Compound 10 exhibited diabetic neuropathic pain-alleviating effects in a streptozotocin-induced peripheral diabetic neuropathy (PDN) model. The maximum efficacy of compound 10, which was 3-fold more potent than gabapentin, was observed at 1. h after administration, and co-administration of compound 10 with gabapentin showed a considerable synergic effect.

NITROSATION REAGENTS AND METHODS

Provided are compounds that can find use as nitrosation reagents. Provided are nitrosation methods that include reacting a substrate with one of the provided nitrosation reagents and thereby generating a nitrosation product. Provided are kits including a nitrosation reagent. Provided are compositions wherein the nitrosation reagent is enriched in the 15N isotope.

Sultam compound and preparation method thereof

The invention provides a sultam compound and a preparation method thereof. The method provided by the invention specifically comprises the following steps: putting a catalyst C, sulfamide B and an oxidant D into an organic solvent, performing a reaction,

Synthesis of Sultams and Cyclic N-Sulfonyl Ketimines via Iron-Catalyzed Intramolecular Aliphatic C-H Amidation

Cyclic sulfonamides (sultams) play a unique role in drug discovery and synthetic chemistry. A direct synthesis of sultams by an intramolecular C(sp3)-H amidation reaction using an iron complex in situ derived from Fe(ClO4)2 and aminopyridine ligand is reported. This strategy features a readily available catalyst and tolerates a broad variety of substrates as demonstrated by 22 examples (up to 89% yield). A one-pot iron-catalyzed amidation/oxidation procedure for the synthesis of cyclic N-sulfonyl ketimines is also realized with up to 92% yield (eight examples). The synthetic utility of the method is validated by a gram-scale reaction and derivatization of the products to ring-fused sultams.

MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS

Provided herein are compounds, compositions including them, and methods of modulating GPR120 activity and treating diseases mediated by GPR120 by administering such compounds and compositions.

1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS

The present invention provides, in part, compounds of Formula I and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses

Non-Acidic Free Fatty Acid Receptor 4 Agonists with Antidiabetic Activity

The free fatty acid receptor 4 (FFA4 or GPR120) has appeared as an interesting potential target for the treatment of metabolic disorders. At present, most FFA4 ligands are carboxylic acids that are assumed to mimic the endogenous long-chain fatty acid agonists. Here, we report preliminary structure-activity relationship studies of a previously disclosed nonacidic sulfonamide FFA4 agonist. Mutagenesis studies indicate that the compounds are orthosteric agonists despite the absence of a carboxylate function. The preferred compounds showed full agonist activity on FFA4 and complete selectivity over FFA1, although a significant fraction of these noncarboxylic acids also showed partial antagonistic activity on FFA1. Studies in normal and diet-induced obese (DIO) mice with the preferred compound 34 showed improved glucose tolerance after oral dosing in an oral glucose tolerance test. Chronic dosing of 34 in DIO mice resulted in significantly increased insulin sensitivity and a moderate but significant reduction in bodyweight, effects that were also present in mice lacking FFA1 but absent in mice lacking FFA4.

COMPOUNDS CAPABLE OF INHIBITING VOLTAGE GATED CALCIUM ION CHANNEL, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

Disclosed herein are an N-(pyrazolylmethyl)arylsulfonamide derivative useful as a calcium ion channel blocker, a pharmaceutically acceptable salt thereof, and the medicinal use thereof as a therapeutic agent using its calcium ion channel blocking effect.

Catalytic asymmetric Exo-selective [C+NC+CC] reaction

A catalytic asymmetric version of the exo-selective [C+NC+CC] reaction is reported. This multicomponent reaction utilizes a readily prepared achiral glycyl sultam as the "NC" component and commercially available catalyst components. The method can be applied to a variety of aldehydes ("C" component) and activated alkenes ("CC" component) to provide substituted pyrrolidines in good yields and high enantioselectivities. Of particular note is the ability to employ labile enolizable aldehydes (e.g., acetaldehyde and propionaldehyde) in this reaction.

Saccharin derivatives as inhibitors of interferon-mediated inflammation

A series of novel, saccharin-based antagonists have been identified for the interferon signaling pathway. Through in vitro high-throughput screening with the Colorado Center for Drug Discovery (C2D2) Pilot Library, we identified hit compound 1, which was the basis for extensive structure-activity relationship studies. Our efforts produced a lead anti-inflammatory compound, tert-butyl N-(furan-2-ylmethyl)-N-{4-[(1,1,3-trioxo-2,3-dihydro-1λ6,2- benzothiazol-2-yl)methyl]benzoyl}carbamate CU-CPD103 (103), as a potent inhibitor using an established nitric oxide (NO) signaling assay. With further studies of its inhibitory mechanisms, we demonstrated that 103 carries out this inhibition through the JAK/STAT1 pathway, providing a drug-like small molecule inflammation suppressant for possible therapeutic uses.